Acellular vaccines for preventing whooping cough in children

Zhang, Linjie; Prietsch, Sílvio O. M.; Axelsson, Inge; Halperin, Scott A.

doi:10.1002/14651858.cd001478.pub3

Cited by 5 publications

(4 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of the whole cell pertussis vaccine was estimated at 89% [4, 21–23]. Based on clinical trial data, we also assumed that the vaccine efficacy after vaccination in the first year [24, 25], after booster vaccination at age 4 years [24, 25], and after adolescent booster vaccination would be 89% [26–28]. …”

Section: Methodsmentioning

confidence: 99%

Modelling the impact of extended vaccination strategies on the epidemiology of pertussis

Rozenbaum

Vries

et al. 2011

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYThe aim of this study was to investigate the optimal pertussis booster vaccination strategy for The Netherlands. A realistic age-structured deterministic model was designed. Assuming a steady-state situation and correcting for underreporting, the model was calibrated using notification data from the period 1996–2000. Several sensitivity analyses were performed to explore the impact of different assumptions for parameters surrounded by uncertainty (e.g. duration of protection after natural infection, underreporting factors, and transmission probabilities). The optimal age of an additional booster dose is in the range of 10–15 years, and implementation of this booster dose will reduce both symptomatic and asymptomatic infections, although the incidence of symptomatic infections in older age groups will increase. The impact of the different assumptions used in the model was in general limited. We conclude that over a wide range of assumptions, an additional booster dose can reduce the incidence of pertussis in the population.

show abstract

Section: Methodsmentioning

confidence: 99%

Modelling the impact of extended vaccination strategies on the epidemiology of pertussis

Rozenbaum

Vries

et al. 2011

Epidemiol. Infect.

View full text Add to dashboard Cite

show abstract

“…In particular, 5-component acellular pertussis vaccines are currently used in the Netherlands for infants (Pediacel (R) and Infanrix-hexa (R) ) and for boostering at the age of 4 (Infanrix-IPV (R) ). These multi-component (≥3 components) vaccines have a higher efficacy than one- and two-component acellular vaccines and have not been assessed inferior to the best whole cell vaccines on a statistically significant level [27], [28]. Based on clinical trial data the efficacy of an acellular adolescent booster vaccine for adolescents was also estimated at a quite similar level [29]–[31].…”

Section: Methodsmentioning

confidence: 99%

Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model

et al. 2010

View full text Add to dashboard Cite

BackgroundDespite widespread immunization programs, a clear increase in pertussis incidence is apparent in many developed countries during the last decades. Consequently, additional immunization strategies are considered to reduce the burden of disease. The aim of this study is to design an individual-based stochastic dynamic framework to model pertussis transmission in the population in order to predict the epidemiologic and economic consequences of the implementation of universal booster vaccination programs. Using this framework, we estimate the cost-effectiveness of universal adolescent pertussis booster vaccination at the age of 12 years in the Netherlands.Methods/Principal FindingsWe designed a discrete event simulation (DES) model to predict the epidemiological and economic consequences of implementing universal adolescent booster vaccination. We used national age-specific notification data over the period 1996–2000—corrected for underreporting—to calibrate the model assuming a steady state situation. Subsequently, booster vaccination was introduced. Input parameters of the model were derived from literature, national data sources (e.g. costing data, incidence and hospitalization data) and expert opinions. As there is no consensus on the duration of immunity acquired by natural infection, we considered two scenarios for this duration of protection (i.e. 8 and 15 years). In both scenarios, total pertussis incidence decreased as a result of adolescent vaccination. From a societal perspective, the cost-effectiveness was estimated at €4418/QALY (range: 3205–6364 € per QALY) and €6371/QALY (range: 4139–9549 € per QALY) for the 8- and 15-year protection scenarios, respectively. Sensitivity analyses revealed that the outcomes are most sensitive to the quality of life weights used for pertussis disease.Conclusions/SignificanceTo our knowledge we designed the first individual-based dynamic framework to model pertussis transmission in the population. This study indicates that adolescent pertussis vaccination is likely to be a cost-effective intervention for The Netherlands. The model is suited to investigate further pertussis booster vaccination strategies.

show abstract

“…It is possible that such differences in vaccine‐induced immune responses could translate into differences in vaccine efficacy, both in the proportion protected and the duration of protection. Vaccine efficacy of the diphtheria, tetanus, and acellular pertussis (DTPa) vaccine, for example, has been reported as 71–78% for preventing milder symptoms of pertussis and 84% for preventing typical disease, whereas estimates of BCG efficacy against pulmonary tuberculosis in children are highly variable (0–80%) . In addition, clinical trials consistently show lower immunogenicity for vaccines in developing world populations, including the BCG vaccine and those against poliomyelitis and rotavirus .…”

Section: Introductionmentioning

confidence: 99%

The potential of the microbiota to influence vaccine responses

Lynn

Pulendran

2017

Journal of Leukocyte Biology

View full text Add to dashboard Cite

After clean water, vaccines are the primary public health intervention providing protection against serious infectious diseases. Antigen-specific antibody-mediated responses play a critical role in the protection conferred by vaccination; however these responses are highly variable among individuals. In addition, vaccine immunogenicity is frequently impaired in developing world populations, for reasons that are poorly understood. Although the factors that are associated with interindividual variation in vaccine responses are likely manifold, emerging evidence from mouse models and studies in human populations now suggests that the gut microbiome plays a key role in shaping systemic immune responses to both orally and parenterally administered vaccines. Herein, we review the evidence to date that the microbiota can influence vaccine responses and discuss the potential mechanisms through which these effects may be mediated. In addition, we highlight the gaps in this evidence and suggest future directions for research.

show abstract

Acellular vaccines for preventing whooping cough in children

Cited by 5 publications

References 88 publications

Modelling the impact of extended vaccination strategies on the epidemiology of pertussis

Modelling the impact of extended vaccination strategies on the epidemiology of pertussis

Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model

The potential of the microbiota to influence vaccine responses

Contact Info

Product

Resources

About